Ponatinib is highly active when given to patients within 6 months of developing chronic phase chronic myeloid leukaemia, phase II results show, but its toxicity profile is unacceptable for first-line treatment.

Read More:
Vascular side effects prevent first-line ponatinib use in chronic phase CML